Mirati Therapeutics, Inc.
Mirati Therapeutics, Inc.（MRTX）股价预测与分析师目标价
华尔街共识、12 个月目标价、模型推演与 EPS/营收预期 — 来自分析师数据与历史行情。
mrtx · 股价预测 · 31 位分析师（近3月）· FMP · 更新于 2025年4月3日
分析师评级与共识
基于过去 3 个月内 31 位华尔街分析师
Hold
31 位分析师
共识
评级分布
12 个月目标价
High
$247
Consensus
$102
+73.9% upside
Low
$53.00
Median: $66.5 · Last Close: $58.70
12 个月目标价预测
历史收盘价 + 分析师 12 个月目标价预测区间
Consensus Target
$102.10
73.9% upside
High Target
$247
320.8%
Low Target
$53
-9.7%
Current Price
$58.70
as of today
Based on analyst price targets, the MRTX stock price prediction for the next 12 months ranges from $53 to $247. The consensus MRTX price forecast of $102.10 implies 73.9% upside from the current price of $58.70.
短期股价预测
算法生成 · 每日更新
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $58.68 | ↓ 0.03% |
1-day model range: $58.63–$58.73. Peak: $58.73 (-0.03%).
长期股价预测
基于技术分析的股价预测
14 项技术面信号（SMA×6 + EMA×6 + RSI + MACD）· EEAT 方法论透明
Market Sentiment
NEUTRAL
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · MRTX · Jun 9, 2026
最新分析师评级与调整
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2023-12-20 | Citigroup | Downgrade ↓ | Buy→Neutral |
| 2023-11-07 | Stifel | Downgrade ↓ | Buy→Hold |
| 2023-11-07 | Leerink Partners | Downgrade ↓ | Outperform→Market Perform |
| 2023-10-10 | Piper Sandler | Downgrade ↓ | Overweight→Neutral |
| 2023-10-09 | Scotiabank | Upgrade ↑ | Sector Underperform→Sector Perform |
| 2023-10-09 | Piper Sandler | Downgrade ↓ | Overweight→Neutral |
| 2023-10-09 | JMP Securities | Downgrade ↓ | Market Outperform→Market Perform |
| 2023-10-09 | B. Riley Securities | Downgrade ↓ | Buy→Neutral |
| 2023-10-09 | Jefferies | Downgrade ↓ | Buy→Hold |
| 2023-10-08 | Jefferies | Downgrade ↓ | Buy→Hold |
Wall Street analysts have recently issued updated ratings on Mirati Therapeutics, Inc. (MRTX) stock. Of the recent 260 rating actions, 32 were upgrades and 35 were downgrades. 31 analysts currently cover MRTX.
分析师推荐趋势
MRTX analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 4 to 0 per month.
财务预测：EPS 与营收一致预期
Revenue This Year
$21M
↓ 67.4% YoY
Revenue Next Year
$27M
↑ 26.9% YoY
EPS This Year
$-10.42
EPS Next Year
$-12.82
↑ 23.0% YoY
EPS ForecastReported vs Estimated
Analysts forecast MRTX EPS of $-10.42 for the current fiscal year, based on estimates from 6 analysts. The MRTX revenue forecast is $21M for the current year. These are analyst consensus estimates via FMP / S&P Global.
关于预测与目标价
MRTX 股价预测由两类独立数据源支撑：来自 31 位华尔街分析师（S&P Global / FMP）的共识评级，以及基于历史日终价计算的技术分析。MRTX 的共识目标价为 $102.10（+73.9% 上行空间），分析师共识为 Hold。
MRTX 的短期预测（明日）为 $58.68（-0.03%）。
Mirati Therapeutics, Inc. 在 NASDAQ 上市，代码 MRTX。MRTX 在 2027 年的整体展望偏中性/分化，在覆盖分析师中约 45% 对应 Hold 共识。
常见问题
MRTX 预测 · 8 个问题根据 31 位华尔街分析师，MRTX 的 12 个月平均目标价为 $102.10，最高 $247.00、最低 $53.00。若有图表，中位目标价可在上方查看。相对当前价 $58.70，隐含约 +73.9% 的上行空间。
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.